#United States #Carlsbad #Tyra Biosciences #BCAN #UTUC

Tyra Biosciences and BCAN Establish UTUC Awareness Day

Tyra Biosciences, Inc. (Nasdaq: TYRA), a biotechnology firm specializing in next-generation precision medications, has partnered with the Bladder Cancer Advocacy Network (BCAN) to declare May 21 as Upper Tract Urothelial Cancer (UTUC) Awareness Day. This collaboration seeks to raise awareness of UTUC, a rare cancer impacting the kidney and ureters, and to highlight the urgent need for advancements in treatment options for patients experiencing this challenging condition.

Understanding UTUC

UTUC is characterized by alterations in the FGFR3 gene, which are common in patients suffering from this cancer type. Current standard therapies typically involve invasive procedures like endoscopic tumor removal or, in advanced scenarios, nephroureterectomy, a surgery that can cause significant long-term health issues. Unfortunately, effective kidney-sparing treatment alternatives remain scarce, creating a critical demand for innovative solutions that address these challenges.

The partnership between TYRA and BCAN emphasizes the importance of supporting the UTUC patient community, many of whom report feeling disconnected and overwhelmed due to the lack of available resources and information. Meri-Margaret Deoudes, CEO of BCAN, emphasized the organization's commitment to fostering a supportive environment, stating, "As a rare form of urothelial cancer, UTUC has historically received limited attention despite the significant impact on patients' lives. Establishing UTUC Awareness Day represents a pivotal step towards increasing recognition, fostering patient communities, and promoting education and advocacy concerning this disease."

Efforts in Research and Treatment

Both TYRA and BCAN recognize the pressing need for ongoing research into effective treatments. Tyra Biosciences is advancing clinical trials for dabogratinib, an investigational oral FGFR3-selective inhibitor, as part of their efforts to provide better options for patients with low-grade UTUC (LG-UTUC). This Phase 2 study, known as SURF303 (NCT07265947), holds promise as the only oral treatment currently being developed for this patient group.

Todd Harris, Ph.D., CEO of TYRA Biosciences, stated, "At TYRA, we are dedicated to discovering new therapeutic strategies for patients impacted by urothelial cancers, particularly those who face limited treatment options and considerable burdens. The development of dabogratinib aims to potentially offer a kidney-sparing approach, which is essential as standard treatments often lead to loss of renal function. We are proud to advocate for the UTUC community alongside BCAN."

Through UTUC Awareness Day, TYRA and BCAN hope to galvanize efforts in education, research funding, and treatment innovation. The establishment of this awareness day reflects a broader commitment to address the needs of the UTUC community, promoting hope and support for patients and their families.

Conclusion

As the healthcare landscape evolves, initiatives like UTUC Awareness Day are crucial for shedding light on rare cancers and driving progress in treatment and advocacy. The collaboration between Tyra Biosciences and BCAN marks a meaningful step toward enhancing the lives of individuals facing the challenges of UTUC, ensuring that they feel supported and empowered in their fight against this disease.

For further information regarding TYRA's clinical studies or to access more resources related to UTUC, please visit the official TYRA Biosciences website.